Similar Articles |
|
Chemistry World March 1, 2010 Andy Extance |
Bacterial mix sweetens biodrug synthesis Bacteria welcome in the human gut are set to become better factories for biological drugs thanks to modified genes from another, gastroenteritis-causing, species. |
Chemistry World June 29, 2015 |
Organic odysseys Valuable compounds often come from the strangest places, and in such small concentrations that synthetic chemistry has to step up. |
Chemistry World July 2008 Ananyo Bhattacharya |
Sparks of creation Chemists are at the forefront of synthetic biology, the burgeoning field that could soon create artificial life. |
Chemistry World August 27, 2013 Polly Wilson |
Hydrogel treatment targets tumors Hydrogels of cancer drug taxol injected directly into tumors have been shown to be more effective at inhibiting tumor growth than intravenous taxol injections of four times the dosage. |
The Motley Fool November 18, 2004 Charly Travers |
A Glimpse of Bristol-Myers' Portfolio Late-stage drugs are crucial for a company beset with patent losses. |
Chemistry World June 30, 2011 Laura Howes |
Chemically evolved bacteria European scientists have created an Escherichia coli strain with a separate genome using chlorinated DNA. |
Wired August 2003 Jennifer Kahn |
The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine. |
Bio-IT World July 14, 2004 Karen Hopkin |
'Omics: The NextGeneration Researchers in industry and academia are cataloging collections of biochemical compounds (metabolomics) to determine how they respond when organisms are challenged by drugs, disease, or stress (metabonomics). |
The Motley Fool May 15, 2007 Mike Havrilla |
On the Threshold at Sonus The pharma is testing one drug that could be used to treat several types of cancer. Investors, take note. |
BusinessWeek April 11, 2005 Arlene Weintraub |
Drawing A Bead On Side Effects Drug makers are figuring out ways to make some old remedies such as Propulsid safer. |
The Motley Fool September 18, 2006 Brian Lawler |
Cell Therapeutics' New Mate The biopharmaceutical company removes some uncertainty by teaming up with Novartis. Investors, take note. |
Chemistry World July 1, 2013 James Urquhart |
Antibiotic research hits a sweet spot UK researchers have found a way to weaken the molecular armour of Escherichia coli to allow the host's immune system to attack and kill the pathogen. |
The Motley Fool January 27, 2005 Wherrett & Yelovich |
Billion-Dollar Markets Nanoparticulates offer golden opportunities for investors... if you know where to look. |
The Motley Fool January 28, 2011 Brian Orelli |
Celgene Needs a Rocket Ship Celgene really needs a hit from Abraxane and other drugs it may license or purchase. |
BusinessWeek April 11, 2005 Arlene Weintraub |
A Nano Drug's Giant Promise After seeking FDA approval for a decade, American Pharmaceutical Partners' Abraxane, which offers a less-toxic cancer treatment, has doctors and investors hopeful. |
Bio-IT World October 2006 Eric K. Neumann |
The Advantages of a Drug Safety Commons Once a Drug Safety Commons has been established, a variety of derivative applications will be developed that can access as well as update the information in organized ways and used by industry researchers internally. |
Chemistry World September 26, 2006 Fiona Case |
Synchronised Delivery for DNA and Drugs Polymer capsules that can simultaneously deliver drug molecules and DNA into a cell could boost the power of cancer treatments. |
The Motley Fool April 29, 2004 Bill Mann |
Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses. |
The Motley Fool September 25, 2007 Brian Orelli |
No Drugs, No Rally Sonus Pharmaceuticals' lead drug fails in phase 3 trials, so the stock crashes. |
Bio-IT World July 11, 2002 Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
The Motley Fool March 30, 2011 Brian Orelli |
Amgen's Long Shot Comes Up Short Amgen and Takeda Pharmaceutical's motesanib didn't extend overall survival in lung cancer patients when combined with Bristol-Myers Squibb's Taxol and carboplatin. |
Chemistry World June 1, 2012 Philip Ball |
A dose by any other name With graphene, fullerenes and dendrimers, scientists have shown that they can sometimes master the trick of balancing euphony, descriptiveness and specificity in chemical naming. |
The Motley Fool April 28, 2009 Brian Orelli |
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. |
Chemistry World October 28, 2008 Hayley Birch |
Drug sandwich baits E. coli toxins Polymer scaffolds that pin molecules together at multiple binding sites can trap and destroy E. coli toxins by locking them to immune proteins, researchers based in Canada and Japan have found. |
The Motley Fool May 28, 2010 Brian Orelli |
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. |
The Motley Fool June 15, 2010 Brian Orelli |
Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug. |
BusinessWeek June 16, 2011 Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
The Motley Fool March 30, 2010 Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
The Motley Fool April 8, 2008 Brian Orelli |
Songs of the One-Drug Wonders Will these companies become big-name drugmakers or get lost in history? Let's take a quick look at: Abraxis Bioscience... Elan... Amylin Pharmaceuticals... Onyx Pharmaceuticals... |
The Motley Fool November 11, 2010 Brian Orelli |
ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial. |
PC Magazine August 8, 2008 Carol L. Gonsher |
Storing Data on Living Computers DNA stores an awful lot of information, so why not computer data? |
Chemistry World February 19, 2009 Nina Notman |
Nanoparticles give cancer drug a boost US scientists have taken a novel step towards fighting the reoccurrence of lung cancer, using drug delivering nanoparticles. |
Chemistry World June 24, 2014 Elisabeth Ratcliffe |
Human protein cleans drinking water Researchers in Japan have shown that they can remove Escherichia coli from drinking water using tiny tubes made of human serum albumin. |
The Motley Fool July 28, 2006 Jack Uldrich |
Tiny Particles Cause a Big Storm for Abraxis Elan sues Abraxis Bioscience for patent infringement. Abraxis' stock, which has fallen nearly 60% from its 52-week high, might make a compelling buy for more risk-tolerant investors. |
Chemistry World March 5, 2012 Harriet Brewerton |
Picturing Bacteria on Your Phone US scientists have developed a device that, when attached to a mobile phone, can detect small amounts of Escherichia coli in liquid samples. |
The Motley Fool January 25, 2006 Stephen D. Simpson |
Bristol-Myers Catches a Cold Tough days are coming, but so are promising new drugs. It's understandable why long-term investors might be willing to hold on and see how things work out. |
BusinessWeek February 16, 2004 Catherine Arnst |
Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs. |